Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIVEX study of SIR9900 in VEXAS syndrome
2025-524918-28-00Phase 2Authorised
- Sponsor
- Sironax
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in VEXAS syndrome (VEXAS) comparing SIR9900 with Placebo (2 arms). Primary endpoints: Safety in Part A, Early Treatment Failure in Part A and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
SIR9900
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on 2025-524918-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524918-28-00.